AsiaIPEX is a one-stop-shop for players in the IP industry, facilitating IP trade and connection to the IP world. Whether you are a patent owner interested in selling your IP, or a manufacturer looking to buy technologies to upgrade your operation, you will find the portal a useful resource.

Back to search results

Patient-derived, Murine Model of Prostate Cancer

Technology Benefits: In broad terms, the PCSD1 model is more representative and predictive of the bone metastatic prostate cancer tumors found in patients. Specifically: Current prostate cancer cell line (SCID mouse) xenograft models, include: - PC3, which produces purely osteolytic lesions in intra-tibial xenografts; - LAPC9, which produces purely osteoblastic lesions; and for over a decade, PCSD1 has low passage numbers with cryopreserved cells from the primary tumor and subsequent passages. Transplantation into Rag2-/-;IL2Rγc-/- immunodeficient mice (which completely lack B, T and NK cells) provides superior, highly efficient engraftment relative to SCID mice, which are not completely immunodeficient. - VCaP, which produces mixed osteoblastic/osteolytic lesions While these three collectively comprise the range of bone lesions produced by prostate cancer metastases, none recapitulates the full range of mixed osteoblastic/osteolytic lesions, observed in most patients. Where the previous models have been passaged ex vivo for over a decade, PCSD1 has low passage numbers with cryopreserved cells from the primary tumor and subsequent passages.Transplantation into Rag2-/-;IL2Rγc-/- immunodeficient mice (which completely lack B, T and NK cells) provides superior, highly efficient engraftment relative to SCID mice, which are not completely immunodeficient.

Technology Application: The PCSD1 xenograft model is helping unravel the complex mechanisms of interaction of prostate cancer with the bone microenvironment and patient variation in response to therapies. Enigmas that may now be addressed include: Treatments for patients with significantly lowered PSA levels after treatment with abiraterone, who still showed positive bone scans, and Treatments for patients treated with Cabozantinib (c-Met TKI, XL184), who showed dramatic reductions in positive bone scans but, paradoxically, no decrease in their PSA levels.

Detailed Technology Description: Injection of patient-derived prostate cancer bone metastasis specimens into femurs of immunodeficient (Rag2-/-;IL2Rγc-/-) mice engendered serially transplantable tumors, which have been used to dissect the complex interactions between prostate cancer and the bone. In addition, the model enables new approaches to understand mechanisms of therapy-resistance that inevitably arise for bone metastatic prostate cancer.

Supplementary Information: Patent Number: WO2013056174A1
Application Number: WO2012US60128A
Inventor: JAMIESON, Christina | KULIDJIAN, Anna, A. | JAMIESON, Catriona, H. | KANE, Christopher, J. | MASUDA, Koichi | WU, Christina, CN | RAHEEM, Omer, A.
Priority Date: 13 Oct 2011
Priority Number: WO2013056174A1
Application Date: 12 Oct 2012
Publication Date: 18 Apr 2013
IPC Current: A01K0067027 | C12N000510 | G01N003315
Assignee Applicant: The Regents of the University of California
Title: XENOGRAFT MODEL OF HUMAN BONE METASTATIC PROSTATE CANCER | MODÈLE DE XÉNOGREFFE DU CANCER DE LA PROSTATE AVEC MÉTASTASES OSSEUSES CHEZ L'HOMME
Usefulness: XENOGRAFT MODEL OF HUMAN BONE METASTATIC PROSTATE CANCER | MODÈLE DE XÉNOGREFFE DU CANCER DE LA PROSTATE AVEC MÉTASTASES OSSEUSES CHEZ L'HOMME
Summary: The method (M1) is useful for generating bone metastasis-derived prostate cancer xenograft model, preferably non-human animal or animal model and PCSD1 model. The method (M2) is useful for testing drug, compound, diet, therapy or treatment. The method (M3) is useful for screening therapeutic agents for prostate cancer (all claimed).
Novelty: Generating bone metastasis-derived prostate cancer xenograft model for screening therapeutic agents for prostate cancer, by providing immunodeficient non-human animal, and injecting human prostate cancer cells into animal e.g. rat

Industry: Disease Diagnostic/Treatment

Sub Category: Cancer/Tumor

Others

State Of Development

PCSD1 is ready for use in pre-clinical drug testing as well as basic research on castration-resistant prostate cancer and tumor growth in the bone microenvironment/niche. Validation includes:

Tumors were characterized as advanced, luminal epithelial prostate cancer (PSA+, AR+, TMPRSS2;ERG-) by RT-PCR and immunohistochemical biomarker analyses.
MicroCT scanning showed that PCSD1 intra-femoral xenografts induced mixed osteoblastic/osteolytic lesions that closely recapitulated bone metastatic prostate cancer lesions in patients.

Intellectual Property Info

Worldwide rights available; Pending patents available under confidentiality.

Related Materials

Raheem, O. et al., (2011) A novel patient-derived intra-femoral xenograft model of bone metastatic prostate cancer that recapitulates mixed osteolytic and osteoblastic lesions, J Transl Med., 9:185.
Ma, W., et al. (2012) NOTCH1 signaling promotes human T-cell Acute Lymphoblastic Leukemia initiating cell regeneration in supportive niches, PLoS One 7(6): e39725.
Sturge J, et al., (2011) Bone metastasis in prostate cancer: emerging therapeutic strategies. Nat Rev Clin Oncol., 8(6):357-68.
Mehra R, Kumar-Sinha C, et al., (2011) Characterization of bone metastases from rapid autopsies of prostate cancer patients. Clin Cancer Res.17(12):3924-32.
Lopez-Barcons, LA, (2010) Human prostate cancer heterotransplants: a review on this experimental model. Asian J Androl., 12(4):509-18.
Virk MS, et al., (2009) Influence of simultaneous targeting of the bone morphogenetic protein pathway and RANK/RANKL axis in osteolytic prostate cancer lesion in bone. Bone. 44(1):160-7.

Tech ID/UC Case

22747/2012-105-0

Related Cases

2012-105-0

*Abstract: Bone metastases are detected in 80-100% of men who die of prostate cancer and such metastasis leads to painfully debilitating fractures, spinal compression and rapid decline. In addition, metastases to bone tissue often become resistant to standard therapies including androgen deprivation, radiation and chemotherapy. The scarcity of primary human prostate cancer bone metastasis tissues has crippled direct analysis and options to better understand the disease. In addition, spontaneous bone metastasis of prostate cancer in murine models, even to implanted human bone, is an exceedingly rare event. The development of a patient-derived xenograft (PDX) model of bone metastatic prostate cancer presents new options for improving therapeutic options.

*Principal Investigator: Name: Catriona Jamieson
Department:

Name: Christina Jamieson
Department:

Name: Chistopher J Kane
Department:

Name: Anna Kulidjian
Department:

Name: Koichi Masuda
Department:

Name: Omer Raheem
Department:

Name: Christina Wu
Department:

Country/Region: USA

For more information, please click Here